A 35-year-old woman was admitted to the Nephrology and Dialysis Unit of Pisa University for hypertension, hypokalaemia, renal impairment, proteinuria and hyperglycaemia. plasma renin activity (PRA) and plasma aldosterone were elevated, but Doppler ultrasound and angio-computed tomography (CT) of renal arteries were normal. Abdomen CT revealed only a left adrenal mass, and measurement of catecholamines suggested the diagnosis of pheochromocytoma. Biochemical findings suggestive of hyperparathyroidism were also detected, but a multiple endocrine disorder was excluded by genetic analysis. Pathology examination confirmed the pheochromocytoma and immunohistochemistry also showed positivity for parathyroid hormone. After surgery, disappearance of the symptoms and normalization of all haemodynamic and humoral parameters was observed. This is a rare case of pheochromocytoma responsible for secondary hyperaldosteronism, hyperparathyroidism, proteinuric renal disease and diabetes mellitus.
Introduction
Pheochromocytoma (PHEO) is a rare tumour of chromaffin cells with variable and unforeseeable clinical presentation. The multiple and different effects of catecholamines (metanephrine, normetanephrine and dopamine) and of biologically active co-secreted peptides explain the possible wide variety of symptoms and signs of PHEO [1] .
We report on a very exceptional case of a young woman affected by sporadic adrenal PHEO responsible for secondary hyperaldosteronism, hyperparathyroidism, proteinuric renal disease and diabetes.
Case report
A 35-year-old woman was admitted to the Nephrology and Dialysis Unit of Pisa University on May 2009 complaining of malaise, headache, weakness, polydipsia, polyuria and leg cramps. Physical examination was normal apart from clinic blood pressure, which ranged between 170/100-190/105 mmHg and 166/108-170/120 mmHg in supine and standing position, respectively. Biochemistry was in the normal range, except for hypokalaemia (2.6-2.9 mEq/L), mild reduction in renal function (serum creatinine, 1.1 mg/dL; creatinine clearance, 88 mL/min; glomerular filtration DTPA TC99m, 75 mL/min × 1.73 mq), proteinuria (1.5-2.5 g/24 h) and fasting hyperglycaemia (129-137 mg/dL). No subclinical organ damage of hypertension (heart, blood vessels and fundus oculi) was found.
Hypertension, electrolyte disorder and proteinuric renal disease prompted us to investigate renal function and the renin-angiotensin system (RAS). A clear secondary hyperaldosteronism was found due to elevated values of PRA (33.2-28.5 ng/mL/h, normal values (n.v.) 0.5-5.0 ng/mL/h), active renin (27.1 pg/mL, n.v. < 21.3 pg/mL) and plasma aldosterone (ALD: 103.0-88.6 ng/dL, n.v. 3.0-30 ng/dL). However, Doppler ultrasound/angio-computed tomography (CT) of renal arteries and renal CT showed no significant stenosis or renal abnormalities (Figure 1 ). Moreover, PRA and ALD proved to be normally suppressed (1.7 versus 27.0 ng/mL/h and 4.0 versus 81.1 ng/dL, respectively) after the saline loading test, thus excluding autonomous hormone secretion. Abdomen CT scan, unexpectedly, revealed a non-homogeneous mass (4 cm in diameter) in the left adrenal gland with contrast enhancement (Figure 1) . Evaluation of the adrenal medulla suggested diagnosis of PHEO due to very high levels of plasma noradrenaline (3912-4018 pg/mL, n.v. < 600 pg/mL), Chromogranin A (>1200 ng/mL, n.v. < 100 ng/mL) and of urinary normetanephrines (5863-4826 μg/24 h, n.v. < 600 μg/24 h). A single abdominal left adrenal location was confirmed by I-131 MIBG scintigraphy (Figure 1) .
Before surgery, a detailed family history and extensive hormonal examination were performed to rule out a hereditary disorder. Family history was negative and thyroid hormones, plasma calcitonin (<2 pg/mL) and thyroid/parathyroid ultrasound were within the normal range. Only plasma human parathyroid hormone (hPTH) values, measured by a chemiluminescent immunoassay for quantitative determination of intact human PTH (DiaSorin Inc., Stillwater, MN; the Liaison N-TACT PTH assay: 100% cross-reactivity for hPTH 1-84, 52% for hPTH 7-84 and 0.1% for the other fragments), were repeatedly above the normal range (119-256 pg/mL, n.v. < 75 pg/mL), a finding associated with reduction in tubular phosphate reabsorption (TRP, 76.5%) and low renal threshold phosphate concentration (TmPO4/Glomerular Filtration Rate (GFR), 2.0 mg/dL). Additionally, high-normal serum calcium (9.7-10.3 mg/dL) and low-normal serum phosphate (2.6-2.8 mg/dL) were observed. Urinary phosphate excretion (525 mg/24 h), plasma 25-vitamin D (35 ng/mL, n.v. 11-70 ng/mL) and 1,25-vitamin D (49 pg/mL, n.v. 20-67 pg/mL) were normal. However, at genetic analysis, no germ-line mutations in known susceptibility genes for PHEO (RET, VHL and succinil-dehydrogenase, SHD) were detected. On the basis of these data, we proposed to investigate a possible coexistent primary hyperparathyroidism. However, we decided to postpone the study until haemodynamic conditions were stabilized.
The patient underwent surgery and macroscopic and microscopic features of the surgical specimens, including immunohistochemical analysis of the tumour cells (positivity for: Chromogranin A, Synaptophysin, NSE and S-100), were in agreement with the presence of PHEO. After removal of the mass, a dramatic fall in catecholamine/metanephrine levels occurred, followed by disappearance of the symptoms and normalization of blood pressure and of all humoral and hormonal parameters, including PTH (Table 1) . For this reason, we performed immunohistochemical analysis, using polyclonal rabbit anti-human PTH to detect human intact PTH (Biomeda; Histo-Line Laboratories, Milan, Italy), in order to evaluate whether PHEO cells were able to cosecrete other substances involved in the patient's clinical presentation. Effectively, positivity immunostaining for PTH was found in most tumour cells of PHEO, suggesting direct ectopic PTH production by the tumour (Figure 2 ).
Discussion
The case herewith reported is very unusual and provides interesting insight into the pathophysiology of PHEO. It confirms that PHEO may have different clinical presentations, according to the amount and type of catecholamine secreted and number and biological activity of cosecreted peptides.
In this patient, we observed secondary hyperaldosteronism with very high active renin and PRA levels, high plasma ALD and hypokalaemia. Renovascular hypertension, reninoma and other causes of RAS activation were excluded. RAS activation was shown to be associated with PHEO since its removal completely and persistently normalized renin and ALD values. The possibility that PHEO was able to cosecrete renin-like compounds, though reported in the literature [2] , was ruled out in our case, as the saline loading test normally suppressed plasma renin and ALD. This indicated that the physiological mechanisms controlling renin release were preserved and that renin was not secreted autonomously [3] . Thus, according to the reported close association between plasma catecholamines and renin [4] and the demonstration of juxtaglomerular cell hyperplasia induced by catecholamines in patients with PHEO [5] , we believe that both β-receptor-mediated renin secretion [4, 6] and catecholamine-mediated systemic and also renal artery vasospasm/vasoconstriction may represent the cause of RAS activation in our patient. Secondary hyperaldosteronism explains hypokalaemia which in turn, in association with increased catecholamines, would favour diabetes mellitus and nephrogenic diabetes with polyuria. Thus, volume depletion may have further activated RAS.
Another rare clinical finding in our patient was proteinuria. No history of nephropathy was reported, and malignant hypertension, a well-known cause of proteinuria, was unlikely. In fact, blood pressure target organs were normal, and proteinuria immediately and persistently disappeared after surgery, thus suggesting that renal damage was functional and that haemodynamic (high blood pressure) and hormonal (high catecholamine levels) conditions were involved in this process. Although chronic high ALD levels may likewise be associated with microalbuminuria/proteinuria [7] , we believe that glomerular hyperfiltration secondary to systemic hypertension and to efferent arteriole vasoconstriction due to RAS activation may take part in this process. Reduced tubular protein reabsorption may also be involved in regards to tubular damage related to (i) hypokalaemia, (ii) ischemia in connection with catecholamine-induced vasospasm/vasoconstriction and possibly to (iii) hyperparathyroidism. Additionally, a paraneoplastic proteinuria and a proteinuric effect (through vasopressin V2 receptors) of RAS-mediated vasopressin increase cannot be ruled out [8] . Whatever the cause, normalization of haemodynamic conditions and of humoral/hormonal parameters was associated with stable disappearance of proteinuria. Finally, hyperparathyroidism with hypercalcaemia was another clinical presentation of the patient. Since PHEO was not associated with multiple endocrine neoplasia, PTH normalization after surgery suggested that chromaffin cells of PHEO were able to synthesize and release this hormone. According to this hypothesis, immunohistochemistry proved to be positive for PTH, thus explaining the coexisting high hormone levels. Detection of immunostaining with anti-PTH antibody is very surprising since, while PTH-related peptide positivity has been reported in malignant tumours and more rarely in PHEO cells [9] , ectopic PTH production is documented only in rare cases of malignant and benign tumours [10] .
In conclusion, we report on a singular case of sporadic PHEO presenting with reversible secondary hyperaldosteronism and hyperparathyroidism, proteinuric renal disease and diabetes mellitus. High blood pressure values and direct and indirect biological damage produced by catecholamines and cosecreted peptides confirm the wide functional potentiality of the chromaffin tissue and explain the variety of clinical presentation of this tumour.
